Andrew Hodgkinson - LeMaitre Vascular President
| LMAT Stock | USD 100.15 0.23 0.23% |
President
Mr. Andrew Hodgkinson Senior Vice President Clinical, Regulatory and Quality Affairs of LeMaitre Vascular Inc. Mr. Hodgkinson joined us in 2000 as Production Supervisor and was promoted to Production Manager in 2003, Director, Manufacturing in 2006, Director, Clinical Affairs in 2007, Vice President, Clinical and Regulatory Affairs in 2008 and Vice President, Clinical, Regulatory and Quality Affairs in 2011 since 2012.
| Age | 48 |
| Tenure | 13 years |
| Address | 63 Second Avenue, Burlington, MA, United States, 01803 |
| Phone | 781 221 2266 |
| Web | https://www.lemaitre.com |
LeMaitre Vascular Management Efficiency
The company has return on total asset (ROA) of 0.0872 % which means that it generated a profit of $0.0872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1334 %, meaning that it created $0.1334 on every $100 dollars invested by stockholders. LeMaitre Vascular's management efficiency ratios could be used to measure how well LeMaitre Vascular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.1 in 2025, whereas Return On Tangible Assets are likely to drop 0.06 in 2025. At this time, LeMaitre Vascular's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 418.7 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 1.8 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Daniel Woolson | ICU Medical | 48 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| Stewart Strong | Haemonetics | 58 | |
| Roy Galvin | Haemonetics | 54 | |
| Michelle Basil | Haemonetics | 52 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| James McAvinn | Milestone Scientific | N/A | |
| Randal Golden | The Cooper Companies, | 57 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Brian Andrews | The Cooper Companies, | 46 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Anila Lingamneni | Haemonetics | 57 | |
| James Darecca | Haemonetics | 50 | |
| Holly Sheffield | The Cooper Companies, | 54 | |
| Virginia Sanzone | ICU Medical | 50 | |
| Jan Verstreken | Hologic | 57 | |
| Daniel McBride | The Cooper Companies, | 56 | |
| Jennifer Schneiders | Hologic | 56 | |
| William Burke | Haemonetics | 52 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Howard Yu | Envista Holdings Corp | 51 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 |
LeMaitre Vascular Leadership Team
Elected by the shareholders, the LeMaitre Vascular's board of directors comprises two types of representatives: LeMaitre Vascular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LeMaitre. The board's role is to monitor LeMaitre Vascular's management team and ensure that shareholders' interests are well served. LeMaitre Vascular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LeMaitre Vascular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Roberts, President Director | ||
| Jonathan Ngau, Senior Technology | ||
| George LeMaitre, Chairman and CEO | ||
| Trent Kamke, Sr. VP of Operations | ||
| Kimberly Cieslak, Vice President - Marketing | ||
| Ryan Connelly, Vice President - Research & Development | ||
| Laurie Churchill, Senior Vice President General Counsel | ||
| Maik Helmers, Senior Europe | ||
| Joseph Pellegrino, CFO, Principal Accounting Officer and Secretary | ||
| Stephane Maier, Vice President EMEA Operations | ||
| Daniel Mumford, Director Resources | ||
| David Hissong, General Counsel | ||
| Andrew Hodgkinson, Senior Vice President - Clinical, Regulatory and Quality Affairs |
LeMaitre Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LeMaitre Vascular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.14 B | ||||
| Shares Outstanding | 22.48 M | ||||
| Shares Owned By Insiders | 8.87 % | ||||
| Shares Owned By Institutions | 93.10 % | ||||
| Number Of Shares Shorted | 1.3 M | ||||
| Price To Earning | 38.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for LeMaitre Stock Analysis
When running LeMaitre Vascular's price analysis, check to measure LeMaitre Vascular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LeMaitre Vascular is operating at the current time. Most of LeMaitre Vascular's value examination focuses on studying past and present price action to predict the probability of LeMaitre Vascular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LeMaitre Vascular's price. Additionally, you may evaluate how the addition of LeMaitre Vascular to your portfolios can decrease your overall portfolio volatility.